2-(3,4-dimethylphenyl)furan | 80866-22-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3,4-dimethylphenyl)furan
• CAS: 80866-22-4
• 化学式: C₁₂H₁₂O
• 分子量: 172.227
• InChiKey: LLNMYNKMQBZVBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-溴呋喃 、 magnesium,1,2-dimethylbenzene-5-ide,bromide 在 1,2-双(二苯基膦)乙烷氯化镍 作用下， 以 乙醚 为溶剂， 反应 16.0h， 以98%的产率得到2-(3,4-dimethylphenyl)furan
  参考文献：
  名称：

  Regiospecific synthesis of arylfurans employing a nickel(II)-phosphine complex as a catalyst in the homolytic cross-coupling of Grignard reagents to halofurans

  摘要：

  DOI：

  10.1021/jo00347a049

文献信息

• THIAZOLIDINONE COMPOUNDS AND USE THEREOF
  申请人：National Health Research Institutes

  公开号：US20170253569A1

  公开（公告）日：2017-09-07

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

  一种含有化合物（I）的药物组合物，用于治疗与阿片受体相关的疾病。还公开了一种使用这种化合物治疗阿片受体相关疾病的方法。进一步公开了两组式（I）的噻唑烷酮化合物：（i）每种化合物的对映体过量大于90%；（ii）每种化合物被氘取代。
• PRIDGEN, L. N.;JONES, S. S., J. ORG. CHEM., 1982, 47, N 8, 1590-1592
  作者：PRIDGEN, L. N.、JONES, S. S.

  DOI：——

  日期：——
• [EN] TOLUIDINE SULFONAMIDES AND THEIR USE AS HIF-INHIBITORS<br/>[FR] TOLUIDINE SULFONAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU FACTEUR HIF
  申请人：EUROPEAN MOLECULAR BIOLOGY LAB EMBL

  公开号：WO2010085968A1

  公开（公告）日：2010-08-05

  The present invention provides compounds of formula (I) wherein R1 is a monocyclic 5- or 6 membered heteroaryl; R4 is a monocyclic 5- or 6 membered heteroaryl and the other substituents as defined in the claims, that inhibit cell proliferation and cell divison and that inhibit the activation of Hypoxia Inductible Factor (HIF)--mediated transcription and signaling under hypoxic conditions. In one aspect, the compounds of the present invention are useful for the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularisation. Also provided is a pharmaceutical composition, comprising a compound of the invention and a second therapeutic agent or radiation, useful for the treatment or prevention of the mentioned diseases or disorders.
• [EN] THIAZOLIDINONE COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS DE THIAZOLIDINONE ET LEUR UTILISATION
  申请人：SHIH CHUAN

  公开号：WO2017155910A1

  公开（公告）日：2017-09-14

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.
• Regiospecific synthesis of arylfurans employing a nickel(II)-phosphine complex as a catalyst in the homolytic cross-coupling of Grignard reagents to halofurans
  作者：Lendon N. Pridgen、Stella S. Jones

  DOI：10.1021/jo00347a049

  日期：1982.4